Niraparib with abiraterone acetate and prednisone is in clinical development for patients with prostate cancer which is metastatic (has spread to other parts of the body) and hormone-sensitive, meaning the cancer is being controlled by keeping the testosterone level as low as would be expected if the testicles were removed. Prostate cancer is the most common type of cancer in men in the UK. Alterations to the homologous recombination repair (HRR) pathway (a mechanism by which DNA damage is repaired) may be associated with poorer outcomes. There is therefore a need to develop new treatment options for this population.
Niraparib with abiraterone acetate and prednisone for treating homologous recombination repair-mutated metastatic castration-sensitive prostate cancer
Niraparib with abiraterone acetate and prednisone is in clinical development for patients with prostate cancer which is metastatic (has spread to other parts of the body) and hormone-sensitive, meaning the cancer is being controlled by keeping the testosterone level as low as would be expected if the testicles were removed. Prostate cancer is the most common type of cancer in men in the UK.
Interventions:
Abiraterone acetate (Zytiga; Yonsa)
, Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)
, Prednisone (Decadron; Lodotra)
Indications:
Prostate cancer
Therapeutic Areas:
Male Reproductive Cancer
Year:
2024